The IPO Buzz: Lycia Therapeutics (LYCA) Upsizes IPO & Prices Deal at $18 – Top of Range
Lycia Therapeutics (LYCA) upsized its IPO at pricing to 17.64 million shares – up from 14.7 million shares in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $317.52 million on Thursday night, Oct. 22, 2026. Lycia’s stock is expected to start trading tomorrow – Friday, Oct. 23 – on the NASDAQ. The South San Francisco-based Phase 1 biotech’s IPO had ..
Read more October 22, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Davion Healthcare (Direct Listing) | DAVI | 25.0 | $ 300.0 mil | 10/22/2026 Priced | S/O | S/O |
| Lycia Therapeutics | LYCA | 17.6 | $ 317.5 mil | 10/23/2026 Priced | S/O | S/O |
| Bitari | BIAI | 4.3 | $ 30.0 mil | 10/26/2026 Week of | S/O | S/O |
Last 100 IPOs - October 22, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 42 |
| Number Down: | 55 |
| Number Unchanged: | 3 |
| Percentage Change From Issue Price: | 0.55% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - October 22, 2026
| Number of IPOs priced (Excluding 152 units) : | 134 |
| Number Up: | 51 |
| Number Down: | 80 |
| Number Unchanged: | 3 |
| Total Return From Issue Price: | -1.87% |
| The Nasdaq Composite Index YTD % Change | 35.22% |